Ruijian Pharmaceuticals Completes Nearly 100 Million RMB Series A+ Financing to Advance Clinical Development of NouvNeu001 and NS001

Recently, Wuhan Ruijian Pharmaceutical Technology Co., Ltd. ("Ruijian Pharmaceutical" for short) announced the completion of a nearly 100-million-yuan Series A+ round of financing. This round was led by Changjiang Securities Innovation Investment, with follow-on investments from existing shareholders such as Jinhua United Capital Runpu Healthcare Fund. The proceeds will mainly be used to advance the clinical Phase I study of Ruijian Pharmaceutical's pipeline candidate NouvNeu001 for Parkinson’s disease and simultaneously support the company’s subsequent pipeline NS001 in dual Investigational New Drug (IND) applications in China and the United States.

Founded in 2016, Ruijian Pharmaceuticals is the world's first high-tech pharmaceutical company dedicated to the efficient regeneration of functional cells induced by small-molecule chemicals. Focused on the research and transformation of cell fate regulation mechanisms, Ruijian Pharmaceuticals has established a cell drug development technology platform based on small-molecule chemical induction. The company has implemented a comprehensive and systematic patent layout, primarily targeting specific degenerative, injury-related diseases, tumors, and metabolic system diseases to develop off-the-shelf cell drugs with independent intellectual property rights.